The estimated weight loss and WC reduction at 24 months were −3.50 [−5.21; −1.80] kg and −6.23 [−7.94; −4.76] cm, respectively. TS was also associated with a significant reduction in fat and with an increase in lean mass as well as with a reduction in fasting glycemia and insulin resistance. In addition, an improvement of lipid profile (reduction in total cholesterol as well as of triglyceride levels and an improvement in HDL cholesterol levels) and in both systolic and diastolic blood pressure was observed. Conclusions Present data support the view of a positive effect of TS on body composition and on glucose and lipid metabolism. In addition, a significant effect on body weight loss was observed, which should be confirmed by a specifically designed RCT.
Introduction
Overweight and obesity have become an epidemic problem, on the rise not only in Western societies, but also in developing countries. Body mass index (BMI) is universally used to categorize overweight and obesity, along with its severity [1, 2] . Although the classification of obesity is based on BMI, the crucial abnormality that characterizes this condition is an excess of fat mass, rather than body weight. In addition, BMI does not take into account the accumulation of visceral fat, which characterizes the most morbigenous form of obesity: visceral (central) obesity, i.e., abdominal fat depots around visceral organs. Waist circumference (WC) is an alternative measure that reflects visceral adiposity, and it is superior to BMI in predicting cardiovascular (CV) disease [3] . This is largely explained by the association of increased visceral adipose tissue (VAT) with a range of metabolic and CV abnormalities included in the construct of metabolic syndrome (MetS) [4, 5] .
MetS and visceral obesity are nowadays considered the main determinants of male hypogonadism (HG), in particular when these conditions become manifest during adulthood (testosterone deficiency syndrome, TDS). In fact, both cross-sectional and longitudinal studies indicate that obesity increases the risk of testosterone deficiency ( [6] [7] [8] [9] [10] , see in Refs. [11] [12] [13] [14] for review).
Testosterone (T) is an anabolic hormone that plays a relevant role in decreasing VAT accumulation and increasing muscle mass. Preclinical studies show that, in differentiating adipocytes, an androgen-dependent increase in Wnt signaling promotes differentiation of resident mesenchymal cells into myocytes and osteocytes, while suppressing their commitment toward the adipocyte lineage and terminal differentiation, by inhibiting the expression of peroxisome proliferator-activated receptor gamma (PPARγ) and CAAT/enhancer-binding protein alpha (CEBPα), the central regulators of adipogenesis [4, 15] . Accordingly, several observational and register studies indicate that T supplementation (TS) in hypogonadal men is able to dramatically reduce waist circumference, body weight and BMI in a time-dependent fashion [16] [17] [18] [19] [20] [21] [22] [23] [24] . In longer-term studies assessing anthropometric parameters, results with testosterone undecanoate (TU) in TDS-associated obesity seem to be superior even to other lifestyle or medical interventions and comparable to those obtained with the most invasive therapies, such as bariatric surgery [25, 26] .
Randomized controlled trials (RCTs), designed for a specific purpose, are generally considered the gold standard for investigating the efficacy of a particular health intervention, including medical treatment. In fact, RCTs are at the top of the evidence-based hierarchy of the best available data to develop clinical guidelines aimed at standardizing procedures and therapies. However, we are unaware of studies specifically designed to obtain evidence for evaluating the effect of TS on body composition in HG, at least as a primary endpoint. Information derived from RCTs designed for other purposes is available, although they are more fragmentary and often contradictory. In this case, meta-analyses may aid in clinical reasoning and establish a more solid foundation for causal inferences, because they are able to overcome between-studies heterogeneity and to address questions across many different research domains for which data sources are conflicting or lack adequate statistical power. A recent meta-analysis on all available RCTs comparing the effect of TS on different metabolic endpoints showed that TS determined a significant reduction of fat and an increase in lean mass as well as a reduction in fasting glycemia and insulin resistance [27] . Similar results were observed for total cholesterol and triglyceride levels when only RCTs enrolling hypogonadal (total T < 12 mol/L) subjects were considered [27] . Interestingly, the effect of TS on body composition was even better when subjects with metabolic diseases at enrollment were considered [27] . This finding is not surprising since previous meta-analysis of available evidence documented that TS was associated with an improvement of metabolic profile either in patients with MetS or in those with type 2 diabetes mellitus (T2DM) [4] . However, in the aforementioned meta-analysis on body composition, TS does not appear to induce weight loss. The dual, opposite effects of TS on body composition, i.e., an increase in lean mass and a reduction in fat mass, might justify the overall null efficacy of TS on body weight or BMI. The peculiar study design of these RCTs might also justify the lack of efficacy of TS on weight parameters. In fact, RCTs are performed under idealized and rigorously controlled conditions, which are different from everyday clinical practice. Hence, results of RCTs offer an indication of the efficacy of an intervention rather than its effectiveness in everyday practice. For example, patients enrolled in RCTs are not representative of the whole population of patients in the real world, because of the exclusion of certain categories of subjects (e.g., elderly subjects, those with comorbidities, individuals with low compliance to treatments). In addition, patients who participate may receive better care, regardless of which arm of the trial they are in. In contrast, observational and register studies maintain the integrity of the context in which medical care is provided [28, 29] . As a result, whereas RCTs provide an indication of the minimal effect of an intervention, observational studies offer an estimate of the maximal one. In addition, observational studies are more likely to provide an indication of daily medical practice and to measure the effectiveness of an intervention in 'real world' scenarios [28, 29] .
The aim of this study is to systematically review and meta-analyze available observational and register studies reporting data on body composition in studies on TS in HG. A comparison with results obtained in RCTs [27] was also performed.
Methods
This meta-analysis was performed according to the MOOSE Guidelines for Meta-Analyses and Systematic Reviews of Observational Studies [30] .
An August 31, 2014 . In addition, completed but still unpublished trials evaluating the effects of TS on different outcomes were identified through a search on the http://www.clinicaltrials.gov website. The identification of relevant studies was performed independently by two of the authors (V.G., G.C.), and conflicts resolved by the third investigator (A.A.). We did not employ search software. We hand-searched bibliographies of retrieved papers for additional references. The principal source of information was derived from published articles; if data were missing from the publication, an attempt at retrieval was made through the clinicaltrial.gov website.
Study selection
We included all observational studies, comparing the effect of TS on different endpoints ( [16] [17] [18] [19] [20] [21] ; see also Fig. 1; Tables 1, 2, 3 ). Studies not specifically evaluating body composition or glycometabolic outcomes were excluded from the analysis (not shown [57-62; see also Table 4 ). Studies using androgens other than TS as well as studies with simultaneous treatment with other hormones, and drugs were also excluded, unless there was a clearly defined treatment arm that received only T treatment. To compare results in observational studies to those reported in RCTs [27] , we restricted the analysis to the same time frame as before (August 2014).
Outcome
The principal outcome of this analysis was the effect of TS, as compared to baseline, on body composition modification including fat and lean mass ( Table 2) . Secondary outcomes included several other glycometabolic parameters (Table 2) .
Quality assessment
The quality of trials was assessed using the Cochrane criteria ( [63] ; see also Table 3 ). In particular, we evaluated the following criteria: the weaknesses of the designs that have been used (such as noting their potential to ascertain causality), the execution of the studies through a careful assessment of their risk of bias, especially the potential for selection bias and confounding to which all observational studies are susceptible, and the potential for reporting biases, including selective reporting of outcomes. For each study, we also assessed how the population was selected, the duration and route of TS, and the adequacy of study follow-up [64] .
Statistical analysis
Heterogeneity was assessed by using I 2 statistics. Even when low heterogeneity was detected, a random-effects model was applied, because the validity of tests of heterogeneity can be limited with a small number of component studies. To estimate possible publication or disclosure bias, we used funnel plots and the Begg adjusted rank correlation test [65, 66] . However, because these tests have low statistical power when the number of trials is small, undetected bias may still be present. In addition, since in some trials the significance of between group comparisons (p) was not reported, the analysis was performed evaluating endpoint values of each parameter in different treatment groups, in a non-paired fashion (non-paired analysis). Considering that most of the studies, which did not describe p values, reported nonsignificant differences across groups, the mean (paired) analysis, which excludes those data, is likely to overestimate the effect of treatments. On the other hand, the non-paired analysis is a very conservative approach, which could underestimate treatment effect. Since body fat mass and lean mass were evaluated through different approaches and expressed in different ways, the mean difference for each study was divided by the pooled estimate of the SD, in order to express the effect size for each study in a common metric, namely the standardized mean difference (SMD). According to Cohen [66] , a small treatmenteffect size is considered to be about 0.2, a medium effect size to be about 0.5, and a large effect size to be about 0.8. All other data were expressed as weight mean differences. A meta-regression analysis was performed to test the effect of different parameters on TS reduction in weight and waist circumference. All analyses were performed using Comprehensive Meta-analysis version 2, Biostat (Englewood, 1 3 NJ, USA). Multivariate analyses were performed on SPSS (Statistical Package for the Social Sciences; Chicago, USA) for Windows 22.0.
Results
Out of 824 retrieved articles, 32 were included in the study (Fig. 1) . The characteristics of the retrieved trials (including parameters on trial quality) and type of outcomes considered are reported in Tables 1, 2 , and 3. Retrieved studies included 4513 subjects, all receiving TS. TS was administered in different doses, formulations, and cohorts (Table 1) .
When compared to a previous meta-analysis [27] of RCT only, patients included in observational trials were younger and had lower T levels, higher prevalence of diabetes mellitus, and longer duration of follow-up (see Table 5 ). Conversely, no difference between groups in BMI levels at enrollment was observed (Table 5) .
Body composition
Among studies reporting several outcomes, 19 included information on weight (Table 2) . I 2 was 92.44, p < 0.0001. Funnel plot and Begg adjusted rank correlation test suggested no major publication bias (Kendall's τ: −0.14; p = 0.38, see also Fig. 2 ). TS was associated with a reduction in body weight (Fig. 3a) , BMI (Fig. 3b) , and WC (Fig. 3c ). In addition, meta-regression analysis showed that the reduction in both weight and WC at endpoint was more evident in longer studies, in a time-dependent manner ( 
Studies included in quantitative synthesis (meta-analysis) N 38
Studies excluded N 6 (see Table 4 )
Unpublished studies N 68
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Studies excluded (Randomized Controlled Trials) N 65 (Fig. 4c, d , respectively) and more hypogonadal subjects (Fig. 4e, f Information on fat mass and lean mass was available from 11 and 10 studies, respectively ( Table 2) . TS was associated with a significant reduction in fat and with an increase in lean mass (Table 6 ; see also Supplementary Figure 1, panels A-B) .
Glyco-metabolic profile and blood pressure
TS was associated with a reduction in fasting glycemia and insulin resistance (IR), as detected by HOMA-IR index (Table 6; (Table 6 ; see also Supplementary Figure 1 , panels E-F). Finally, an improvement in HDL cholesterol levels as well as in both systolic and diastolic blood pressure was detected (Table 6 ; see also Supplementary Figure 1 , panels G-I).
Discussion
The present meta-analysis of observational studies on TS in HG shows that TS is associated with weight loss. On average, TS is associated with a pooled 3-kg decrease in weight, one-point decrease in BMI, and a 6-cm loss in WC. This result is at variance with that of RCTs, as previously reported [27] . In general, RCTs are considered more reliable for the assessment of treatment effects, because they allow a comparison with a randomly allocated control group, thus eliminating spontaneous variations of the parameters investigated, together with the effect of being included in a study [28, 29] . On the other hand, RCTs are performed on a selected population of patients, who may differ from that of subjects actually receiving the treatment in clinical practice [28, 29] . In fact, the observational studies summarized here enrolled patients who were younger and showed a lower baseline T level and higher prevalence of diabetes mellitus than those included in RCTs. Metaregression analysis indicated that a higher prevalence of diabetes mellitus, lower age, and a lower baseline T are predictors of a greater weight loss with TS. It is conceivable that these differences might explain, at least partially, the different weight outcomes observed between observational studies and RCTs. Another, even more relevant, difference between observational studies and RCTs is the duration of follow-up (only 9 months in RCTs, on average, vs. more than 18 months in observational studies).
Weight loss, like weight gain, is a slow process, which requires sufficient time. It is not surprising that, if a treatment produces weight loss, this effect becomes evident only in studies of sufficient duration. In particular, the positive effect of TS on weight loss in observational studies, involving unselected cohorts of HG men, was apparent only after 24-but not 12-month follow-up. It is interesting to note that only few RCTs extended their follow-up past this limit. Theoretically, according to equations derived from the present meta-regression analysis, a 12-kg weight loss and 14.5-cm reduction in WC can be extrapolated [24] . A total weight loss of 17.4 ± 0.5, 25.3 ± 0.5, and 30.5 ± 0.7 kg, in obesity classes I, II and III, respectively, was reported. These figures even extended our meta-analytic broadcast, most probably because in the Saad study [24] only obese subjects were enrolled. Accordingly, more pronounced positive effects of TS on weight were evident also in other cohorts considering obese subjects [22, 23, 67] . The study cited above [24] clearly shows that weight loss with T, as well as with any weight-reducing treatment, is greater in patients with higher baseline body weight. In the evaluation of the results of TS on weight loss, we should consider that both RCTs and observational studies enrolled a relevant proportion of lean and mildly overweight subjects, Table 4 Studies that met inclusion criteria but did not provide data for meta-analysis First Authors Years Short summery of the study and main conclusions Conway et al. [57] 1988 With the aims of comparing the pharmacokinetics and pharmacodynamics of three different formulations of T, 15 hypogonadal men were studied. However, those results were not included in our meta-analysis since the group of participants consisted of not all unaware patients Sorva et al. [58] 1988 The study consisted in evaluating the TRT effects on serum lipids and lipoproteins in 13 hypogonadal men. This work was ruled out given that the patient group was made up of prepubertal and postpubertal men Ozata et al. [59] 1996 The effects of gonadotropin and T therapies on lipids and lipoprotein(a) were studied in 31 hypogonadal males. The data were not considered for our study since the patients were prepubertal men Tripathy et al. [60] 1998 This study aims to look at the T role in developing insulin resistance and other cardiovascular risks factors in men. The data were not included in the meta-analysis as they were obtained from a group of subjects affected by delayed puberty
Andrade et al. [61] 2009 Observational cohort before-and-after study between 2 groups of participants receiving T (T cyprionate 200 mg/3 weeks) or not. There are no data about circulating T both at baseline and at the end of the study. In addition, the data are not complete Wu et al. [62] 2009 Observational cohort before-and-after study comparison in the same group of prepubertal hypogonadic men. TRT (T undercyclate 40 mg o.s.) increased weight and BMI. The data were not considered for our study since the patients were prepubertal boys 
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in whom a larger weight loss is unlikely. It should be noted that none of the studies analyzed here were designed as weight loss studies. The profound weight loss achieved in the long-term studies was rather an unexpected and accidental finding. In contrast, weight loss studies exclusively enroll obese subjects who have the intention to lose weight.
In addition, TS is known to increase muscle mass [27] , possibly attenuating the reduction in total body weight. The present meta-analysis confirmed the increase in lean mass, which had already been reported in RCTs [27] . In fact, the reduction of fat mass, which had been observed also in RCTs, was confirmed here for observational studies. Unfortunately, this parameter was available only for a fraction of studies, simply because data obtained in "real-life" settings would not include measurement of body composition at regular intervals.
Considering the T anabolic properties, the role of TS in improvement frailty and in particular muscle strength and physical performance has attracted considerable attention [14, 68, 69] . However, the currently available evidence indicates that the T alone is relatively ineffective in improving the aging-associated impaired elderly physical performance [4] . Accordingly, a recent RCT evaluating the effect of T gel or placebo in 790 men aged 65 years or older on several outcome showed no benefit with respect to vitality or walking distance [70] .
In line with its positive effects on body composition, we also report here a significant T-induced improvement in lipid profile, which was only marginally apparent in RCTs [27] . A significant, beneficial effect of TS was also noted for both systolic and diastolic blood pressure, most probably reflecting the improvement in body composition. Finally, we here confirm [27, [71] [72] [73] The improvement of several CV risk factors observed in this study might suggest a possible reduction in CV risk. However, CV safety remains one of the most controversial issues related to TS in aging men. So far, six systematic meta-analyses on the effect of TS as derived from placebo-controlled RCTs are currently available [74] [75] [76] [77] [78] [79] . The only meta-analysis reporting an increased CV risk associated with TS was published 3 years ago in BMC Medicine by Xu et al., [79] . The authors used as the primary outcome "composite CV events," defined as anything reported as such by the study's authors [79] . The construct "composite CV-related events" included all investigator-reported adverse events assigned to the CV system. The Xu et al. [79] meta-analysis was in contrast with all the previous ones [75] [76] [77] , and in fact, all the other metaanalyses showed no significant difference between the T and placebo groups for all incident CV events, or for each type of event (CV death, fatal and non-fatal myocardial, revascularization procedures, arrhythmia, cerebrovascular events), except the increase in hematocrit over 50 %, which was significantly more prevalent in the T group [75] . In line with the latter evidence, we performed the last, updated, systematic review and meta-analysis of RCTs on TS, using the incidence of major adverse cardiac events (MACE) as a primary endpoint [74] . MACE are easier to detect and less controversial in diagnosis and are the events requested by regulatory authorities to verify the safety of newly registered drugs (http://www.fda.gov/Drugs/) [74] . By metaanalyzing the largest number of studies collected so far, any increase in CV risk associated with TRT was not observed when either composite or single CV endpoints were considered [74] . Hence, available data suggest that when hypogonadism is properly diagnosed and replacement therapy correctly performed CV risk is not an issue [14] . Accordingly, the Coordination Group for Mutual Recognition and Decentralised Procedures-Human (CMDh), a regulatory body representing European Member States-after a review by the European Medicines Association (EMA)'s Pharmacovigilance Risk Assessment Committee (PRAC)-has agreed by consensus that there is no consistent evidence of an increased risk of heart problems with T medicines in HG men (http://www.ema.europa.eu/ema/index. jsp?curl=pages/medicines/human/referrals/Testosteronecontaining_medicines/human_referral_prac_000037.jsp& mid=WC0b01ac05805c516f). The interpretation of the results of the present metaanalysis should be cautious because of the relevant potential biases. Although specific analyses seem to exclude a publication bias in this case, significant results are more likely to be published, thus providing a potential distortion in favor of weight loss. In addition, in observational studies the completeness of follow-up and the management of missing data are crucial; it can be speculated that patients experiencing a relevant weight loss have a higher chance of reporting body weight to investigators, thus producing an overestimate of weight loss. Long-term RCTs involving young HG subjects with obesity having weight loss as a primary endpoint are needed to confirm the surprising results obtained in the observational studies scrutinized here.
It is also important to note, however, that diagnosis of HG allows only for a short period of placebo-controlled design, because the condition is associated with an increased risk of osteoporosis or other metabolic and sexual side effects. Hence, long-term, placebo-controlled studies are scarcely feasible. Although the evidence strength is usually lower than that of RCTs, observational studies have the advantage of reflecting the actual prescribing of T in health care and the advantages of including broader patient populations also from non-teaching hospitals, all resulting in higher generalizability.
In conclusion, the lesson derived from everyday clinical practice, summarized here, supports the view of a positive effect of TS on body composition and on glucose and lipid metabolism, as already suggested by the meta-analysis of RCTs [27] . Observational studies also suggest a significant effect on body weight loss, which should be confirmed by a specifically designed RCT.
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